Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Beyond the genome: An integrated multi-omics approach to uncover histone ptm-driven metabolic and proteomic regulation in AML

Laura Corveleyn, Jolien Vanhooren, Boris Vandemoortele et al. Nov 03, 2025 pp. 1448-1448 10.1182/blood-2025-1448

Abstract * Laura Corveleyn, Jolien Vanhooren and Boris Vandemoortele are shared first authors ** Vanessa Vermeirssen, Ti...

Outcomes of NPM1-mutated AMLs in first hematological relapse and prognostic value of MRD

Sofiane Fodil, Matthieu Duchmann, Edoardo Tamellini et al. Nov 03, 2025 pp. 5294-5294 10.1182/blood-2025-5294

Abstract Background & Objectives. The prognosis of NPM1m AML after first hematological relapse and the predictive value of NPM1m MRD wit...

Type 2 diabetes screening and management in individuals with sickle cell disease is compromised by the predominant reliance on glycosylated haemoglobin (HbA1c)

Aparna Chitharanjan, Rupesh Rajendran, Ramsha Nabeel et al. Nov 03, 2025 pp. 4446-4446 10.1182/blood-2025-4446

Abstract Coexisting diabetes mellitus and sickle cell disease (SCD) markedly increases the risk of organ damage, particularly nephropathy. A...

Impact of long-term luspatercept treatment on iron parameters in patients with transfusion-dependent and non-transfusion-dependent β-thalassemia: Results from the phase 3b long-term follow-up study

Ali Taher, Khaled Musallam, Maria Domenica Cappellini et al. Nov 03, 2025 pp. 4695-4695 10.1182/blood-2025-4695

Abstract Introduction: Iron overload is a common complication of chronic anemia and ineffective erythropoiesis in β-thalassemia. Initial ana...

Tumor-derived microRNA-125a impairs CART cell function and predicts treatment failure in B cell malignancies

Olivia Sirpilla, Ismail Can, Kun Yun et al. Nov 03, 2025 pp. 2321-2321 10.1182/blood-2025-2321

Abstract Background Chimeric antigen receptor T cell (CART) therapy has revolutionized treatment for hematologic malignancies. However, dura...

LS1781 (Arm E): Phase II clinical trial to assess the safety and efficacy of high dose IV ascorbic acid with decitabine in newly diagnosed TET2 mutant chronic myelomonocytic leukemia (CMML)

Abhishek Mangaonkar, Jenna Fernandez, Ashya Burgess et al. Nov 03, 2025 pp. 2079-2079 10.1182/blood-2025-2079

Abstract BACKGROUND: DNA methyltransferase inhibitors (DNMTi) are US FDA approved for the management of CMML. These agents are associated wi...

PITPβ loss disrupts malignant pAKT activation to ameliorate Jak2 V617F-induced myeloproliferative neoplasms (MPN) in mice

Nikita Vantsev, Liang Zhao, Charles Abrams et al. Nov 03, 2025 pp. 5534-5534 10.1182/blood-2025-5534

Abstract Myeloproliferative Neoplasms (MPN) is a group of phenotypically defined blood cancers that affect thousands of people around the wo...

Randomized phase II dose optimization study of inobrodib (CCS1477), in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM)

Nisha Joseph, Victoria Campbell, Charlotte Pawlyn et al. Nov 03, 2025 pp. 4035-4035 10.1182/blood-2025-4035

Abstract Background Inobrodib (CCS1477/Ino) is a first-in-class potent, selective, and orally bioavailable inhibitor of the bromodomains of p...

Single-cell sequencing reveals transcriptional and metabolic divergence of bone-involved multiple myeloma

Dian Tong, Xiaoyan Qu Nov 03, 2025 pp. 7487-7487 10.1182/blood-2025-7487

Abstract Multiple myeloma (MM) presents with heterogeneous clinical symptoms, commonly categorized as CRAB features—hypercalcemia, renal fai...

Clinical significance of dynamic changes in platelet satellitism during multiple myeloma therapy

Moe Kadono, Yuta Inoue, Shoso Munemasa et al. Nov 03, 2025 pp. 6597-6597 10.1182/blood-2025-6597

Abstract Background: Platelet satellitism (PS) is a rare form of pseudothrombocytopenia characterized by rosette-like clusters of platelets...

Outcomes and treatment strategies following CD20/CD3 bispecific antibody failure in non-Hodgkin's lymphoma: A retrospective single-center study

Sun-Hye Ko, Tomohiro Aoki, Robert Kridel et al. Nov 03, 2025 pp. 4550-4550 10.1182/blood-2025-4550

Abstract Introduction Bispecific antibodies (BsAbs) targeting CD20 and CD3 have demonstrated promising efficacy in treating relapsed or refr...

Abstract: Maternal and fetal outcomes of pregnancy in essential thrombocythemia: A systematic review.

Harishini Thiruselvan, Nicholas Hsien Han Pua, Alexandra Douglas et al. Nov 03, 2025 pp. 8174-8174 10.1182/blood-2025-8174

Abstract Introduction Approximately 20% of women with essential thrombocythemia (ET) are below the age of 40 with childbearing potential. Ho...

Real-world use, safety, and efficacy of teclistamab with or without prophylactic tocilizumab in relapsed/refractory multiple myeloma; Results from the danish ABCD study.

Astrid Hundeboell Torpe, Jonathan Thorsen, Katrine Fladeland Iversen et al. Nov 03, 2025 pp. 718-718 10.1182/blood-2025-718

Abstract Introduction Teclistamab (Tec) is a bispecific antibody targeting BCMA and CD3 for the treatment of triple-class-exposed (TCE) rela...

Early results from the ongoing pegcetacoplan silo of the international paroxysmal nocturnal hemoglobinuria interest group registry

Carlos de Castro, Peter Hillmen, Peter Blandino et al. Nov 03, 2025 pp. 3189-3189 10.1182/blood-2025-3189

Abstract Introduction: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, serious hematologic condition in which a somatic mutation in bone...

Evaluating the correlation between the quantra hemostasis system and rotational thromboelastometry (ROTEM) for viscoelastic hemostatic assessment: A systematic review and meta-analysis.

Muhammad Usama, Muhammad Rafay Paracha, Anas nasir et al. Nov 03, 2025 pp. 6611-6611 10.1182/blood-2025-6611

Abstract Introduction/Background: Perioperative and trauma-induced coagulopathy considerably contributes to morbidity and mortality. While R...

Early detection of advanced-stage DLBCL using random forest: Uncovering large-scale demographic disparities and site-specific risk patterns

Junho Song, Shrishti Sinha, Asfand Yar Cheema et al. Nov 03, 2025 pp. 7194-7194 10.1182/blood-2025-7194

Abstract Background: Advanced stage (III/IV) diffuse large B-cell lymphoma (DLBCL) at diagnosis is associated with inferior outcomes and oft...

Transformed Waldenström macroglobulinemia is associated with poor outcomes and chemorefractory disease

Jennifer Lue, Michelle Okwali, Venkatraman Seshan et al. Nov 03, 2025 pp. 3573-3573 10.1182/blood-2025-3573

Abstract Background: Histological transformation (HT) of Waldenstrom Macroglobulinemia (tWM) is associated with an overall survival of less...

Asciminib as monotherapy or adjunctive therapy for chronic myeloid leukaemia in blast phase

Carol Yuk-Man Cheung, Ho-Wan Ip, Yok-Lam Kwong Nov 03, 2025 pp. 7297-7297 10.1182/blood-2025-7297

Abstract Introduction Asciminib, a first-in-class Specifically Targeting the ABL Myristoyl Pocket (STAMP) inhibitor, has...

VYSION (VYxeoS liposomal® Italian Observational study iN the real practice): Study design and baseline characteristics

Livio Pagano, Alessandra Sperotto, Elisabetta Todisco et al. Nov 03, 2025 pp. 5212-5212 10.1182/blood-2025-5212

Abstract CPX-351, a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar ratio, was approved for newl...

Model-based evaluation of clinical outcomes for ponatinib versus 2G TKIs in third-line chronic myeloid leukemia (CML)

Jorge Jacob, Jo Sha, Jeroen Jansen et al. Nov 03, 2025 pp. 7952-7952 10.1182/blood-2025-7952

Abstract Background: Patients with chronic phase chronic myeloid leukemia (CP-CML) who have failed treatment with two prior tyrosine kinase...

Efficacy and safety of Daratumumab in relapse/refractory diffuse large B-cell lymphoma

Zetong Hong, ZhaoYang Hong, Tongjuan Li et al. Nov 03, 2025 pp. 7225-7225 10.1182/blood-2025-7225

Abstract Background: Daratumumab is a human immunoglobulin G1 monoclonal antibody that targets CD38 surface antigen, which is overexpressed...

Impact of hospital admissions through the emergency department versus direct admissions for patients with hematologic malignancies: A single site analysis

Benyamin Yaniv, Sean Bowden, Jan Cerny et al. Nov 03, 2025 pp. 2659-2659 10.1182/blood-2025-2659

Abstract Introduction: Patients with hematologic malignancies often visit the Emergency Department (ED) more frequently than patients with c...

Therapeutic preclinical study on the synergy between CD73 inhibitors and selinexor for managing multiple myeloma

Chun-Li Zhang, Qiuxia Wei, Nigmat Rahim et al. Nov 03, 2025 pp. 7455-7455 10.1182/blood-2025-7455

Abstract Abstract Background: Selinexor, a selective nuclear export inhibitor that blocks XPO1 and reduces the translation of oncoprotein mR...

Impact of radiation in limited stage diffuse large B-cell lymphoma in the modern era

Juan Ramirez, Daniel DeAvila, Elisa Galdamez et al. Nov 03, 2025 pp. 1896-1896 10.1182/blood-2025-1896

Abstract Background: The current approach of limited-stage (LS) DLBCL consists of a short course of chemoimmunotherapy (3-4 cycles) followed...

Congenital dyserythropoietic anemia type I: Updated report from the congenital dyserythropoietic anemia registry of North America

Lubna Hamdan, Yasmin Elgammal, Ammar Husami et al. Nov 03, 2025 pp. 4685-4685 10.1182/blood-2025-4685

Abstract Background Congenital dyserythropoietic anemias (CDA) are rare genetic disorders characterized by ineffective e...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page